ExploreWatchlistsPricing
  1. JP-listed companies
  2. Kohjin Bio Co., Ltd.
  3. Financials
  4. Revenue

Kohjin Bio Co., Ltd. (177A)

Market cap
¥5.5B
P/E ratio
50x
Kojin Bio manufactures bacterial culture media, antigen test kits, and cell culture products for research institutions, pharmaceutical companies, and medical facilities.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue (Million JPY)YoY (%)
Mar 31, 20264,939-5.13%
Mar 31, 20255,206+9.14%
Mar 31, 20244,770+0.57%
Mar 31, 20234,743+20.16%
Mar 31, 20223,947+21.40%
Mar 31, 20213,251+15.06%
Mar 31, 20202,826+24.18%
Mar 31, 20192,276

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat